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Abstract (200 words): 24 
Overactive Bladder (OAB) is an idiopathic condition, characterized by urgency, 25 
urinary frequency and urgency incontinence, in the absence of routinely traceable 26 
urinary infection.  We have described microscopic pyuria (≥10 wbc μl-1) in patients 27 
suffering from the worst symptoms.  It is established that inflammation is associated 28 
with increased ATP release from epithelial cells, and extracellular ATP originating 29 
from the urothelium following increased hydrostatic pressure, is a mediator of 30 
bladder sensation.  Here, using bladder-biopsy samples, we have investigated 31 
urothelial ATP signaling in OAB patients with microscopic pyuria. 32 
Basal, but not stretch-evoked, release of ATP was significantly greater from 33 
urothelium of OAB patients with pyuria than from non-OAB patients or OAB patients 34 
without pyuria (<10 wbc μl-1).  Basal ATP release from urothelium of OAB patients 35 
with pyuria was inhibited by the P2 receptor antagonist suramin and abolished by 36 
the hemichannel blocker carbenoxolone, which differed from stretch-activated ATP 37 
release. Altered P2 receptor expression was evident in urothelium from pyuric OAB 38 
patients.  Furthermore, intracellular bacteria were visualized in shed urothelial cells 39 
from ~80% of OAB patients with pyuria. 40 
 These data suggest that increased ATP release from the urothelium, involving 41 
bacterial colonization, may play a role in the heightened symptoms associated with 42 
pyuric OAB patients. 43 
 44 
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Introduction: 46 
Overactive bladder syndrome (OAB) is an idiopathic condition where the bladder 47 
detrusor urinae muscle spontaneously contracts before the bladder is full.  In the 48 
USA, it is ranked in the top 10 of common chronic conditions, competing with both 49 
diabetes and depression, with a reported prevalence of up to 31-42% in the adult 50 
population (2).   51 
OAB is currently characterized by symptoms of urgency, with or without 52 
urgency incontinence, with increased frequency, and nocturia, and in some cases 53 
pain, in the absence of urinary tract infection (UTI) or other defined underlying 54 
pathology (54). The exclusion of infection is determined by failure to isolate ≥105 55 
colony forming units (CFU)/ml of a single species of bacteria from culture of a 56 
midstream urine (MSU) specimen (23) and negative leukocyte esterase and/or 57 
nitrate urinalysis by dipstick (25).  Controversy exists as to whether current methods 58 
used to determine UTI are fully accurate (28).  It has been established that the 59 
bacterial threshold of ≥105 CFU/ml, in the presence of symptoms, is not identified in 60 
approximately 50% of UTI (31).  In addition, we have recently reported the low 61 
sensitivity and specificity of routine urinary dipstick tests (20, 51).  Interestingly, in 62 
recent studies where the threshold has been reduced to ≥102 CFU/ml, bacterial 63 
cystitis has been identified in approximately one third of patients with refractory 64 
OAB, suggesting bacteria may play a significant role in the aetiology of OAB, in at 65 
least a subset of patients with OAB (22, 37, 49).  It is generally accepted, that the 66 
best indicator of UTI is the detection of ≥10 white blood cells (wbc) in 1 µl of fresh, 67 
un-spun, urine examined using a haemocytometer (16, 44); however nowadays this 68 
is not normal clinical practice.  Using this methodology, we have identified a low-69 
grade inflammatory response (pyuria with ≥10 wbc µl-1) in 10-35% of MSU 70 
specimens from patients with OAB (i.e. symptoms of urgency, with or without 71 
urgency incontinence, with frequency and nocturia, in the absence of UTI) (45, and 72 
new data not shown).  Interestingly, our observation is that these patients showed 73 
the worst symptoms of frequency.  Most apposite to this finding is that persistent 74 
inflammation, caused by infection and thereby accompanied by pyuria, is associated 75 
with increased nucleotide (primarily adenosine 5’-triphosphate [ATP]) release from 76 
epithelial cells and nucleotide-activated P2 receptor signaling (4, 5, 36, 55). 77 
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Extracellular nucleotide signaling via P2 receptor activation is important in 78 
the regulation of bladder function (3, 7, 8).  Bladder stretch, during filling, induces a 79 
cytosolic Ca2+ increase via multiple proposed pathways (9) to promote release of ATP 80 
through conductive or vesicular pathways (46), and probably other nucleotides from 81 
superficial urothelium.  Once released, nucleotides bind to P2 receptors on 82 
suburothelial sensory afferents (P2X2, 3 and/or 2/3 subtypes) to trigger nerve 83 
activation and the sensation of bladder fullness and the urge to urinate (52).  Given 84 
the rapid breakdown of extracellular nucleotides by nucleotidases, this route should 85 
involve intermediate signaling steps involving activation of P2 receptors on other 86 
urothelial cells to release additional nucleotides to act in an autocrine/paracrine 87 
manner (17, 19, 48, 58). Nucleotide signaling in human urothelium is enhanced in 88 
interstitial cystitis (IC) in humans and felines (17, 58), a condition symptomatically 89 
similar to OAB yet with the presence of pain and an inflammatory aetiology.  In IC, 90 
stretch-activated ATP release is significantly increased, P2R expression profiles are 91 
altered in the urothelium, and ATP breakdown is purportedly decreased (15, 58).  92 
Interestingly, studies on humans with acute cystitis/urinary infection demonstrate 93 
that uropathogenic E. coli (UPEC) can thrive in the urothelium as intracellular 94 
bacterial colonies resisting host immunity (29), that should be accompanied by 95 
increased nucleotide release from epithelial cells (see paragraph above). 96 
We hypothesize that in a subset of OAB patients (i.e. those with pyuria ≥10 97 
wbc μl-1) there is increased release of ATP, and other nucleotides, from the 98 
urothelium caused by low-grade inflammation, which ultimately results in increased 99 
sensory nerve excitation and the enhanced symptoms of OAB.  Furthermore, in 100 
these patients the low-grade inflammation is associated with intracellular bacteria 101 
colonization of the urothelium.  Here we investigated our hypothesis using human 102 
bladder urothelium obtained using flexible cystoscopy. 103 
 104 
Methods: 105 
Reagents.  Chemical reagents were purchased from Sigma-Aldrich (Poole, UK); with 106 
the exception of suramin obtained from Bayer AG (Leverkusen, Germany) and DAPI-107 
containing microscope slide mountant obtained from Vector Labs (Peterborough, 108 
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UK).  HPLC column and solid phase extraction cartridges were obtained from 109 
Phenomenex (Macclesfield, UK).  110 
 111 
Human tissue and urine samples. All procedures were performed with consent and 112 
approval from the Moorfields and Whittington Hospitals Research Ethics Committee 113 
(London, UK) and the NHS Research Authority South East Coast (Kent).  Informed 114 
written consent was obtained from volunteers involved in the study.  Bladder 115 
biopsies and urine samples were obtained from either the Whittington Hospital 116 
Campus, University College London or Medway Maritime Hospital.  Bladder biopsies 117 
were obtained using a flexible cystoscope under local (or rarely general) anaesthesia.  118 
A catheter specimen of urine (CSU) was obtained from female patients and a MSU 119 
from male patients and non-OAB controls.  Patients with idiopathic OAB were 120 
recruited from Incontinence Clinics and non-OAB controls were recruited from the 121 
Haematuria Clinic.  The inclusion criteria for OAB, reconfirmed at the time of sample 122 
collection, were adults aged ≥18 years of either sex with frequency ≥8 per day, 123 
urgency with or without urgency incontinence, and the absence of a UTI or severe 124 
concomitant urinary tract pathology (e.g. chronic obstruction, catheterisation, 125 
neurological disease, prior radiotherapy, anatomical defects, implanted devices, 126 
pregnancy, bleeding disorders, and/or anticoagulant therapy).  All urine samples 127 
obtained were sent for conventional urinalysis and bacteria culture at the time of 128 
collection, if a UTI was subsequently identified the sample was retrospectively 129 
removed from the study.  The inclusion criteria for non-OAB were a single historical 130 
episode of microscopic haematuria with no underlying pathology.  All OAB and non-131 
OAB patients were additionally investigated for pyuria by trained clinicians as 132 
previously described (20); significant pyuria was taken as of ≥10 wbc μl-1 of fresh un-133 
spun urine.  Thus the following experimental groups were used in this investigation: 134 
i) non-OAB controls, ii) OAB patients without pyuria, that is patients with no wbc or 135 
with <10 wbc μl-1, and iii) OAB patients with pyuria, that is patients with ≥10 wbc μl-136 
1.  Urine was either stored on ice and processed within 1 h (for microscopy) or 137 
immediately snap-frozen and kept at -80°C until the time of processing (for HPLC).  138 
Bladder biopsies were either immediately transported to the laboratory in ice-cold 139 
sterile saline and processed within 1 h of collection or placed in 10% formalin for 48 140 
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h prior to histological scrutiny.  141 
 142 
Bioiopsy histology. Following 48 h in 10% formalin, biopsy tissue was dehydrated 143 
with alcohol and xylene in a vacuum infiltration-processing machine for 12 h.  The 144 
tissue was then impregnated with paraffin wax.  A microtome (Microm HM355S; 145 
Thermo Fisher Scientific, Loughborough, UK) was used to cut sections of 6 µm 146 
thickness.  Slices were placed on a glass slide then dried at 60°C for 10 min.  The 147 
sections were then stained with H&E to evaluate the morphological characteristics of 148 
the tissue. A Leica DM4000B upright light microscope (Wetlar, Germany) was used to 149 
image the sections. 150 
 151 
Biopsy ATP release.  A Luciferin Luciferase ATP Bioluminiscence Assay Kit was used to 152 
quantify ATP release from intact, live, bladder urothelium according to the 153 
manufacturer’s protocol.  In brief, the urothelial cell layer was manually isolated 154 
from the underlying tissue of the bladder biopsy using fine forceps, scalpel and a 155 
dissection microscope (final wet tissue weight being 3.4±0.7 mg [n=33]).  Two 156 
working solutions containing the luciferin luciferase reagents were made up, one in 157 
PBS (phosphate buffered saline [1X] containing [mM]: Na2HPO4 [10], KH2PO4 [1.8] 158 
NaCl [137], KCl [2.7], pH 7.4; Solution-A [isotonic solution]) and one with distilled 159 
water (Solution-B; hypotonic solution).  The intact urothelial cell layer was then 160 
incubated for 1 h in Solution-A (100μl) at 37°Cin a 96-well plate (Nunc, Roskilde, 161 
Denmark).  Basal readings of luminescence were taken after 1 h incubation with the 162 
tissue still immersed in Solution-A.   Stimulated readings of luminescence (i.e. 163 
stretch-evoked ATP release) were taken following the addition of Solution-B (100μl) 164 
for 1 min.  Where stated, stimulated readings of luminescence were taken over a 165 
period of 15 min with 3 min interval recordings to observe degradation of ATP with 166 
time. Two ATP standard curves, one in Solution-A (100 μl volume), and the other in 167 
Solution-A and Solution-B (50:50, 200 μl volume), in combination with blank wells, 168 
were prepared alongside each given experiment with concentrations ranging from 169 
10-10 to 10-7 M.  ATP-evoked luminescence was quantified using a luminometer 170 
(Synergy 2, BioTek, Winooski, USA).  ATP concentration from samples was calculated 171 
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from the ATP standards using linear regression analysis.  All data were normalised as 172 
nM ATP per 5 mg of wet tissue, and stimulated readings presented following the 173 
subtraction of basal readings. In experiments investigating the effect of drugs, the 174 
same protocol was followed, allowing a minimum of 5 min for the drugs to take 175 
effect before luminescence was read. Parallel standard curves were also run in the 176 
presence of drugs to investigate any possible interactions with the luciferin 177 
luciferase reaction. 178 
 179 
Biopsy vesicle staining.  Following immediate transport to the laboratory in ice-cold 180 
sterile saline, biopsy tissue was placed in PBS (1X) and incubated for 1 h at 37 °C to 181 
create resting conditions, or, to imitate stretch conditions (i.e. bladder filling), biopsy 182 
tissue was then incubated in hypotonic PBS (0.5X) for 1 min.  Both the resting and 183 
stretch biopsy tissues were immediately transferred to PFA (4%) for 48 h, before 184 
being wax-embedded and sectioned (as above: Biopsy histology).  The tissue sections 185 
were permeated with a 0.1% Triton X100 solution and incubated with quinacrine 186 
(100 µM) for 30 min before being washed with PBS (1X). Sections were mounted 187 
with DAPI-containing mountant, and visualised under an inverted confocal 188 
microscope using the x63 oil immersion objective (Leica SP5; Wetzlar, Germany).  189 
Using ImageJ software, mean fluorescence intensity was measured in all images 190 
taken from quinacrine-labelled tissue. 191 
 192 
Biopsy RNA extraction and RT-PCR.  Following immediate transport to the laboratory, 193 
in cold sterile saline, the urothelial cell layer was manually isolated from the 194 
underlying tissue of the bladder biopsy using fine forceps, scalpel and a dissection 195 
microscope.  Intact urothelium was homogenised in Tri-reagent and then 196 
freeze/thawed in liquid nitrogen followed by chloroform extraction and ethanol 197 
precipitation.  Precipitated RNA was loaded onto Qiagen RNeasy columns (Qiagen, 198 
Crawley, UK) for DNase treatment and further purification.  RNA concentration was 199 
measured using a spectrometer, Nano N-1000 system (Nanodrop Technologies, 200 
Wilmington, USA). 201 
Total RNA (10 ng) from each sample was reverse transcribed in a 20 µl reaction 202 
volume using the One-step Quantitect Reverse Transcription Kit (Qiagen, Crawley, 203 
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UK) according to manufacturer’s instructions.  Primers for P2 receptor subtypes were 204 
designed using Primer 3 Web-software (Whitehead Institute for Biomedical 205 
Research, Cambridge, USA) and manufactured by Eurofins-MWG (Ebersberg, 206 
Germany) (see Appendix for primers and mRNA accession numbers used).  The real-207 
time PCR, based on SyBR green detection, (Qiagen, Crawley, UK) was performed 208 
using a Chromo-4 thermal cycler (Bio-Rad, Hemel Hempstead, UK) with 2 µl total 209 
RNA.  Using a standard curve, created by duplicate serial dilutions of standard DNA 210 
(target sequence of interest) over 12 logarithmic orders and the thermal cycler 211 
software the relative concentrations of the target amplicons were determined. In 212 
addition, the standard curve was used to verify the linearity of amplification of each 213 
transcript; r2>0.99 in all cases. The relative concentrations of target in each run were 214 
expressed as a ratio to the housekeeping gene, GAPDH. All PCR products were 215 
checked for specificity and purity from a melting curve profile created after each run 216 
by the thermal cycler software. Homology of the PCR products was further checked 217 
for size by agarose gel electrophoresis. 218 
 219 
Urine sediment immunofluorescence.   Fresh urine (50 μl; within 1 h of collection and 220 
stored on ice) was spun onto slides using a cytospin (Sandon Cytospin 4, York, UK) at 221 
800 rpm for 5 min.  The deposit was stained with acridine orange (0.5% in Gey’s 222 
solution) for 30 min; previously shown to fluoresce green in the presence of viable 223 
organism DNA after excitation by a laser at 436-490 nm (12, 32). In order to 224 
differentiate extracellular from intracellular bacteria, a crystal violet counter-stain 225 
(0.1% in 150 mM NaCl) was added to quench the fluorescence of extracellular 226 
microorganisms.  Images were acquired using an upright fluorescence microscope 227 
(Leica DM4000B, Wetlar, Germany), samples were excited at 488 nm and emitted 228 
light collected with a 505-550 nm band pass filter.  On those slides found to have 229 
cells containing bacteria, the deposit was fixed with PFA (4%) for 2 min, then further 230 
treated with anti-Uroplakin III (Santa Cruz Biotechnology Inc; Santa Cruz, USA) for 12 231 
h, a specific marker of urothelial cells (10).  Alexa 555 (Invitrogen, UK) was used as a 232 
secondary antibody and incubated for 2 h, after which the slides were mounted with 233 
DAPI-containing mountant. Images were acquired with a confocal microscope (Leica 234 
SP5; Wetlar, Germany) and Z-series processed using Volocity software (Improvision, 235 
 9
Coventry, UK). Alexa-555 and DAPI were excited at 543 nm and 405 nm, and 236 
emittedlight was collected using a 560 nm long-pass filter and 420 nm long pass 237 
filter, respectively. 238 
 239 
Urine nucleotide and nucleoside quantification. Urine, that had previously been 240 
immediately snap-frozen and kept at -80°C, was thawed and sterile filtered through 241 
a 0.22 µm membrane prior to HPLC analysis.  HPLC analysis was performed as 242 
previously described (11).  In brief, the samples were then subjected to a solid phase 243 
extraction cleaning procedure through Strata-X columns (30 mg/ml; Phenomenex, 244 
Macclesfield, UK).  Elution was achieved using 25 mM ethanolamine at pH 5.0 and 245 
30% methanol in ethanolamine (pH 5.0). A standard curve was prepared alongside 246 
each HPLC experiment consisting of ADP only.  Samples (100 μl) were injected into 247 
the column (Polar-RP 4 μm 80A 250x4.6 mm, Phenomenex, Macclesfield, UK) and a 248 
gradient profile of 2%-30% acetonitrile in phosphate buffer was run for 20 min, with 249 
an additional 15 min stabilisation period. Nucleotides and nucleosides were UV-250 
detected at 254 nm and areas measured with the Agilent software (Agilent 251 
Technologies, Wokingham, UK).  Areas were then adjusted to the SPE cartridge 252 
performance and compared against standard curves to obtain the final 253 
concentration.  Urinary creatinine levels were measured using a commercial test 254 
(R&D Systems, Abingdon, UK) as per manufacturer’s instructions to ensure data 255 
were comparable.  256 
 257 
Statistical analysis.  All numerical data were assessed for normality using the 258 
Kolmogorov-Smirnov test. Significance level was evaluated by two-tailed paired and 259 
unpaired t-tests, parametric and non-parametric one-way ANOVA with appropriate 260 
post-hoc tests. P values less than 0.05 were considered statistically significant.  All 261 
data presented as mean±SEM, and n equals number of patients or samples. 262 
 263 
264 
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Results: 265 
Bladder biopsies obtained from patients using flexible cystoscopy have full-thickness 266 
intact urothelium. H&E staining of wax-embedded and sliced biopsies obtained using 267 
flexible cystoscopy routinely demonstrated intact urothelium of full-thickness in 268 
samples of all three experimental groups of patients (i.e. non-OAB [8 of 8 269 
specimens], OAB without pyuria [11 of 13 specimens], and OAB with pyuria [6 of 6 270 
specimens]) (Figure 1A).  Morphologically distinct umbrella cells were evident on the 271 
luminal side of the urothelium further demonstrating the integrity of the tissue 272 
(Figure 1B).   273 
 274 
Basal ATP release is significantly greater from urothelium of OAB patients with 275 
pyuria. To measure ATP release from microdissected urothelium, we used a luciferin 276 
luciferase assay.  ATP levels became detectable after 15 min and stabilized at 30-40 277 
min (data not shown) and consequently recordings were taken at 60 min.  The subtle 278 
increase in concentration of ATP, which stabilized with time, was taken to represent 279 
basal (i.e. unstimulated) release of ATP.  Basal release of ATP was significantly 280 
greater from urothelium of OAB patients with pyuria (78.1±20.6 nM/5 mg of wet 281 
tissue [hereafter referred to as simply ‘nM’], n=15, P<0.05) than from non-OAB 282 
patients (1.9±1.5 nM, n=9) or OAB patients without pyuria (2.2±1.7 nM, n=33) 283 
(Figure 2A).  Application of a hypotonic solution, to mimic stretch and thus bladder 284 
filling, resulted in substantial, and similar increase in ATP release from the 285 
urothelium of all three experimental groups (non-OAB patients, 129±48 nM, n=9; 286 
OAB patients without pyuria, 38±18 nM, n=33; OAB patients with pyuria, 268±188 287 
nM, n=15) (Figure 2B).  Peak stretch-evoked ATP levels (i.e. the highest 288 
concentration of ATP measured following stimulation) was achieved within 1 min 289 
irrespective of experimental group (n=18; data not shown).  The concentration of 290 
ATP decreased during hypotonic insult suggesting degradation by endogenous tissue 291 
ATPases.  As expected, increasing hypotonicity caused additional ATP release from 292 
urothelium (~2-fold with 25% hypotonic buffer, ~10-fold with 50% hypotonic buffer, 293 
and ~20-fold with 75% hypotonic buffer).  The concentration of ATP released from 294 
urothelium following osmotic insult decreased by 51±8% (n=9) and 52±11% (n=9) 295 
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after 3 min for samples from non-OAB patients and OAB patients with pyuria, 296 
respectively, and levels returned to basal concentrations within 10-12 min in both 297 
cases.  However, for samples from OAB patients without pyuria, the decrease in 298 
concentration of stimulated-ATP release was significantly less after 3 min (26±7%; 299 
n=9; P<0.05) and returned to basal concentrations in ~30 min (Figure 2C).  The 300 
slower rate of stimulated ATP decay seen with urothelium obtained from OAB 301 
patients without pyuria was similar to that with urothelium obtained from non-OAB 302 
patients in the presence of the ATPase inhibitor ARL 67156 (100 μM; n=5) (Figure 303 
2C); ARL 67156 did not alter the peak concentration of stimulation-evoked ATP 304 
release (data not shown).  For ATP concentration measurements following 305 
stimulation, results obtained using HPLC correlated well with results from the 306 
luciferin luciferase assay (data not shown); however it was not possible to use HPLC 307 
to measure basal ATP release as, in some cases, concentrations were below the level 308 
of accurate quantification using the HPLC technique. 309 
 310 
Basal ATP release mechanisms differ from stretch-evoked stimulated release.  We 311 
pharmacologically investigated the molecular mechanism(s) by which ATP is released 312 
(primarily stretch-evoked) from human urothelium obtained from non-OAB patients, 313 
OAB patients without pyuria, and OAB patients with pyuria, using a luciferin 314 
luciferase assay.  Basal ATP release from urothelium of OAB patients with pyuria was 315 
significantly inhibited (by 67±9%, n=3) by the P2 receptor antagonist suramin (1 mM) 316 
and almost abolished by the hemichannel and gap junction blocker carbenoxolone 317 
(CBX, 50μM; n=3), yet, was significantly potentiated (by 74±13%, n=3) by the P2 318 
receptor agonist UTP (1 μM) (Figure 3A).  The UTP-evoked potentiation of ATP was 319 
subtly inhibited (by ~30 nM, n=3) by co-incubation with CBX (50 μM) and 320 
significantly inhibited by co-incubation with suramin (1 mM; P<0.05, n=3), suggesting 321 
at least two mechanisms of ATP release (i.e. hemichannel-mediated and 322 
downstream P2 receptor-evoked) (Figure 3A and 7A).  Botulinum toxin-A (BTX-A; 20 323 
units/ml) known to inhibit vesicular release of ATP, brefeldin-A (BFA; 20 μM) known 324 
to inhibit vesicular trafficking, capsazepine (3 μM) a blocker of stretch-activated TRP 325 
channels, and 4,4'-diisothiocyano-2,2'-stilbenedisulfonic acid (DIDS, 100 μM) a 326 
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calcium-activated chloride channel blocker, did not significantly alter basal ATP 327 
release (all n=3-4) (Figure 3A).  Unfortunately, basal ATP release, as opposed to 328 
stretch-evoked ATP release, from urothelium of non-OAB patients and OAB patients 329 
without pyuria could not be fully investigated due to barely detectable levels of ATP 330 
(see Figure 2A).  However, the effects of UTP (1 μM, n=3) were investigated in these 331 
tissues and found not to significantly increase basal ATP concentration.  Stretch-332 
evoked ATP release (i.e. release evoked by a hypotonic stimulus) from urothelium of 333 
OAB patients with pyuria was significantly inhibited (by 72±14%, n=5) by suramin (1 334 
mM; P<0.05) and almost abolished by BTX-A (20 units/ml, n=3) and BFA (20 μM, 335 
n=3), but unaffected by capsazepine, CBX, DIDS or UTP (n=3-5) (Figure 3B).  336 
Stimulated ATP release from urothelium of non-OAB patients and OAB patients 337 
without pyuria, in addition to being abolished by suramin, BTX-A and BFA, was 338 
significantly inhibited by capsazepine (by 67±11% [n=3] control and 83±8% [n=4] 339 
OAB-pyuria; P<0.05).  340 
Given that BTX-A abolished hypotonicity-evoked ATP release from urothelium 341 
of OAB patients with pyuria (Figure 3B) we investigated whether vesicles were 342 
evident in the urothelium.  Quinacrine staining of wax-embedded and sliced biopsies 343 
demonstrated ATP-containing vesicular structures throughout the urothelium and in 344 
underlying tissue (Figure 4A).  Hypotonic challenge of biopsies from OAB patients 345 
with pyuria prior to wax embedding and slicing resulted in significantly less dense 346 
quinacrine staining (3.9±1.3 arbitary units [AU], n=3, as compared to 0.9±0.3 AU, 347 
n=3), suggesting vesicle emptying following hypotonic stimulation (Figure 4B), which 348 
was inhibited by the addition of BTX-A (1.3±1.3 AU, n=3). 349 
 350 
Altered expression of P2 receptor mRNA in bladder urothelium of OAB patients.  To 351 
quantify the relative abundance of P2 receptor mRNA in microdissected urothelium 352 
of non-OAB patients, OAB patients without pyuria, and OAB patients with pyuria, we 353 
calculated a ratio of the P2 receptor gene of interest to a constitutively expressed 354 
housekeeping gene (GAPDH) using RT-PCR. 355 
We failed to detect significant levels (i.e. >5 arbitrary units) of P2X4 and P2Y4 356 
mRNA in urothelium from any experimental group.  In contrast, significant amounts 357 
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of mRNA were detected for P2X1, 2, 3, 5, 6 and 7, and P2Y1, 2, 6, 11, 12, 13, 14 in 358 
urothelium of non-OAB controls; order of expression:P2Y14>>P2X1, 3, 5, 6 and 359 
7=P2Y1, 6, 11, 12 and 13>P2X2=P2Y2 (Figure 5).  Urothelium from OAB patients without 360 
pyuria showed a significant increase in abundance of P2Y11 and 13 mRNA (by 200-fold 361 
and 10-fold, respectively; n=6; P<0.01).  Whereas, urothelium from OAB patients 362 
with pyuria showed a significant increase in abundance of P2Y2 and 11 mRNA (100-fold 363 
and 50-fold, respectively; n=6; P<0.01) (Figure 5B).  364 
 365 
Intracellular bacteria in shed urothelial cells of OAB patients with pyuria.  To 366 
investigate whether intracellular bacteria are responsible for increased basal release 367 
of ATP from urothelium from OAB patients with pyuria we stained cytospun fresh 368 
urine samples with acridine orange and crystal violet.  Biopsy tissue was not used in 369 
this part of the investigation given its precious nature and the necessity of its use in 370 
mechanistic luciferin luciferase studies.  Planktonic bacteria were observed in 1 of 16 371 
samples from non-OAB patients, whereas, intracellular bacteria were not observed 372 
in any sedimentary cells (8±2 urothelial cells per sample, n=16) (Figure 6A).  373 
Similarly, planktonic bacteria were observed in <10% of samples from OAB patients 374 
without pyuria (n=33) and intracellular bacteria were not observed in any 375 
sedimentary cells (Figure 6B).  The number of sedimentary cells identified as 376 
urothelial cells in urine samples from OAB patients without pyuria was 15±3 (n=33).  377 
Planktonic bacteria were observed in 9 of 16 samples from OAB patients with pyuria, 378 
and intracellular bacteria were observed in sedimentary urothelial cells from 13 379 
samples (19±3 urothelial cells per sample, n=16).  In the 13 samples, 52±9% of 380 
urothelial cells were found to contain intracellular bacteria (Figure 6C). To confirm 381 
that the cells containing intracellular bacteria were urothelial cells, the deposit was 382 
fixed with PFA (4%) then further treated with anti-Uroplakin III (UP-III) and DAPI.  In 383 
all cases, those cells initially identified as urothelial cells by their morphology alone, 384 
were confirmed as urothelial cells by positive UP-III immunofluorescence.  Z-stack 385 
images obtained by confocal microscopy further confirmed the intracellular 386 
localization of bacteria (Figure 6D). 387 
 388 
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Urinary AMP and adenosine levels are elevated in OAB.  Given that basal ATP release 389 
is significantly greater from urothelium of OAB patients with pyuria we investigated 390 
whether this was detectable by HPLC in MSU samples, as well as other nucleotides 391 
(ADP, AMP, GTP, GDP, GMP, UTP, UDP and UMP) and nucleosides (adenosine, 392 
guanosine and uridine) that may be altered (Table 1).  Urinary AMP levels were 393 
significantly greater in samples from OAB patients without pyuria (14.4±8.3 μM, 394 
n=17, P<0.05) and OAB patients with pyuria (8.5±2.3 μM, n=16, P<0.05) than non-395 
OAB patients (2.7±0.5 μM, n=11).  In addition, urinary adenosine levels were 396 
significantly greater in samples from OAB patients without pyuria (228±106 μM, 397 
n=17, P<0.05) than non-OAB patients (61±58 μM, n=11).  Nucleotide and nucleoside 398 
release from biopsy tissue was not investigated using HPLC given the necessity of the 399 
tissue’s use in mechanistic luciferin luciferase studies.  400 
 401 
402 
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Discussion: 403 
The main findings of this investigation revealed that basal release of ATP from the 404 
urothelium is significantly greater for human OAB patients with pyuria ≥10 wbc μl-1 405 
than for OAB patients without pyuria (or with pyuria <10 wbc μl-1) or non-OAB 406 
patients, which may account for the heightened symptoms seen in these patients 407 
(36).  More specifically, we present evidence that (1.) bacteria reside in some 408 
urothelial cells of OAB patients with pyuria ≥10 wbc μl-1, and (2.) a sequential 409 
signaling mechanism occurs whereby (i) basal ATP release from the urothelium is via 410 
hemichannels, (ii) ATP released through hemichannels acts in an autocrine/paracrine 411 
manner by activating P2 receptors expressed throughout the urothelium (likely to be 412 
the P2Y2 subtype, shown here to be upregulated in OAB patients with pyuria), and 413 
(iii) P2 receptor activation causes yet further ATP release from the urothelium via an 414 
undetermined mechanism.  Taken together, these findings lead to the proposal that 415 
in a subset of OAB patients (i.e. OAB patients presenting with pyuria ≥10 wbc μl-1), 416 
there is heightened basal ATP release from, and increased P2 receptor expression in, 417 
the urothelium originating from intracellular bacteria colonization, that culminates in 418 
inappropriate sensory nerve excitation and the symptoms of OAB seen in these 419 
patients (see Figure 7A). 420 
 In addition to reporting altered urothelial ATP release from OAB patients 421 
presenting with pyuria, we also describe stretch-evoked ATP signaling in human 422 
urothelium (which does not significantly differ between OAB patients without 423 
pyuria, OAB patients with pyuria, and non-OAB patients).  Specifically we present 424 
evidence that a sequential signaling mechanism occurs whereby (i) urothelial cell 425 
stretch (as occurs in bladder filling) evokes vesicular ATP release, (ii) ATP released 426 
from vesicles acts in an autocrine/paracrine manner by activating P2 receptors (of 427 
which a variety and abundance are expressed throughout the urothelium), and (iii) 428 
P2 receptor activation causes yet further vesicular ATP release from the urothelium 429 
to presumably activate P2X receptors on suburothelial sensory nerves and therefore 430 
signal bladder fullness (see Figure 7B). 431 
 432 
Mechanisms of urothelial ATP release. 433 
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It is well established that extracellular nucleotide signaling arising from the 434 
urothelium is important in the regulation of bladder function (3, 8).  However, to 435 
date little work has been performed on human urothelium. This, in part, is because 436 
of the reported fragility of the urothelial cell layer and superficial umbrella cells, and, 437 
the logistic difficulty in obtaining tissue samples using the cold-cup biopsy technique 438 
(normally performed under general anaesthesia).  However, here we demonstrate 439 
that full-thickness intact urothelium obtained using flexible cystoscopy, a routinely 440 
used procedure using a fibre optic instrument and not requiring general anesthesia 441 
of the donor, can be used successfully to study the physiology/pathophysiology of 442 
the urothelium in vitro. 443 
 Using urothelium samples, obtained by flexible cystoscopy, we have 444 
presented evidence for an autocrine/paracrine ATP signaling mechanism in human 445 
urothelium that presumably culminates in sensory nerve excitation (see Figure 7).  446 
Our proposed mechanisms of autocrine/paracrine ATP signaling are broadly in 447 
keeping with others.  Autocrine/paracrine signaling by ATP, and other nucleotides, in 448 
epithelial tissues is a well documented phenomenon, especially in renal tissue where 449 
basal ATP release and stretch-evoked ATP release (a function of tubular flow rate) 450 
influence ion and water transport mechanisms, and may even influence intrarenal 451 
blood flow (21, 35, 39, 60).  With respect to the bladder, the group of Birder was the 452 
first to propose that the abundance, and variety, of P2 receptors expressed 453 
throughout the urothelial cell layer might serve to amplify stretch-evoked ATP 454 
signaling (15).  Non-neuronal cellular release mechanisms of ATP are not well 455 
understood.  Proposals to date involve a number of complementary pathways that 456 
include transport via ATP-binding-cassette (ABC) proteins, connexin hemichannels, 457 
large-diameter anion channels and exocytotic vesicular release (1, 31).  Our data 458 
using human urothelium demonstrate ATP release via hemichannels and vesicles 459 
(see Figure 3 and 4).  This investigation extends findings of earlier studies using 460 
urothelium by demonstrating multiple, and different, release mechanisms for both 461 
basal release (in OAB patients with pyuria) and stretch-evoked release (from all 462 
experimental groups).  However, disappointingly we report at least one unidentified 463 
ATP release mechanism in OAB patients with pyuria that is insensitive to all 464 
blockers/antagonists tried (see Figure 7).  It is perhaps prudent to mention at this 465 
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juncture that the effect of bacteria on urothelial cell permeability has not be 466 
investigated, which of course may also account for increased increased basal release 467 
of ATP from the urothelium of patients with OAB and pyuria.  468 
Current OAB therapies include antimuscarinic and/or BTX-A treatment.  The 469 
former is associated with severe side-effects and high rates of withdrawal, and the 470 
latter is notoriously expensive. Our study tested the ability of suramin and BTX-A to 471 
alter the ATP signaling cascades seen in urothelium from OAB patients.  Suramin, 472 
successfully inhibited the exaggerated basal ATP release unique to OAB patients with 473 
pyuria, whereas BTX-A was without effect (see Figure 3A).  However, stimulated ATP 474 
release, similar in non-OAB patients and OAB patients alike, was inhibited by both 475 
suramin and BTX-A (see Figure 3B).  These findings suggest that BTX-A may not be a 476 
suitable therapy for those suffering from OAB with pyuria, and that selective 477 
targeting of urothelial ATP receptors may be an alternative pharmacological strategy 478 
to currently used antimuscarinics in the treatment of OAB (irrespective of pyuria 479 
status). 480 
 481 
P2 receptor expression in urothelium. 482 
Using real time-PCR, we molecularly characterized the P2 receptor subtypes 483 
expressed in urothelium of non-OAB patients, OAB patients without pyuria, and OAB 484 
patients with pyuria. We consistently demonstrated mRNA expression of P2X1-3 and 485 
5-7 receptor subunits, but not P2X4, in samples from all 3 experimental groups.  The 486 
level of expression for each subtype did not significantly differ between 487 
experimental groups.  Given the ability of P2X receptors to form homomeric and 488 
heteromeric ion channels, the possibility exists that up to 10 subtypes of P2X 489 
receptor (P2X1, 2, 3, 5, 6, 7, 1/2, 1/5, 2/3 and 2/6) may be functionally expressed in 490 
human urothelium.  For P2Y receptors, we consistently demonstrated mRNA 491 
expression for all subtypes (P2Y1, 2, 6 and 11-14) with the exception of P2Y4.  However, 492 
levels of P2Y2, 11 and 13 were significantly increased in OAB patients, with an increase in 493 
P2Y2 being specific to OAB patients with pyuria and P2Y13 being specific to OAB 494 
patients without pyuria (see Figure 5). 495 
Our PCR findings demonstrating expression of almost all P2 receptors in 496 
human urothelium are broadly in accordance with previous studies that collectively 497 
 18
reported all P2X (P2X1-7) and P2Y1, 2, 4, 6 and 11 localization/expression in native 498 
urothelium of human, rat, mouse, rabbit, guinea-pig and cat and in a human 499 
urothelial cell line (UROtsa cells) (4, 6, 13-15, 18, 19, 24, 40, 42, 50, 57, 61). That 500 
others have not demonstrated P2Y12-14 expression is perhaps due to the recent 501 
discovery and cloning of these subtypes from human tissue.  Our PCR investigation 502 
also extends findings of earlier studies in which P2 receptor expression in the 503 
urothelium is described for both human and feline IC patients, whereby P2X1 and 3 504 
and P2Y2 are decreased (6, 15). 505 
Interestingly, stimulation of some P2 receptors (P2X2, 4 and 7, and P2Y6) 506 
results in the release of key proinflammatory cytokines (e.g. IL-1ß, IL-6, IL-8 and 507 
TNFα) (3, 47). IL-1, IL-6 and IL-8 have been shown to presage UTI symptoms (27, 53). 508 
Here we present data suggesting that P2Y6 expression may be increased (not quite 509 
significant; Figure 5B) in the urothelium of OAB patients with pyuria, which may be 510 
critical to the release of these cytokines, and amplify the cascade of events leading 511 
to the heightened symptoms of OAB.  512 
 513 
Bacterial colonization of bladder urothelium. 514 
With our findings in mind, the most apposite series of animal experiments have been 515 
reported by the Hultgren group (41, 59). Using a murine model of chronic urinary 516 
infection, they demonstrated the ability of E. coli to colonize the superficial 517 
urothelium forming intracellular bacterial colonies (IBCs). These colonies exhibit a 518 
reduced susceptibility to antibiotics and host immune mechanisms. Electron 519 
microscopy studies showed that colonies formed pod-like protrusions from the cell 520 
wall, with the resident bacteria encased in a polysaccharide-rich matrix surrounded 521 
by a protective shell. Eventually, bacteria detached from the pod and burst into the 522 
bladder lumen where the escaped bacteria then infected fresh cells.  However, in 523 
this study we failed to identify bacteria residing within the urothelial cells lining the 524 
bladder (i.e. in biopsy material) but instead bacteria were identified inside shed 525 
urothelial cells found in urine samples. The possibility exists that the shed umbrella 526 
cells were from the renal pelvis, ureters, urethra and bladder; although unlikely 527 
given that the urine was obtained by CSU sampling.    528 
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Interestingly, Rosen and colleagues have published data that showed IBCs 529 
forming in urothelial cells of patients with acute cystitis (60). UPEC 530 
lipopolysaccharide (LPS) is an extremely potent activator of innate immune 531 
responses acting via binding to CD14 and Toll like receptors in the bladder 532 
urothelium to activate p38 MAP kinase, Ca2+ and cAMP signalling which in turn 533 
triggers IL-6 and IL-8 production. (34, 56). Furthermore, ATP released from both 534 
UPEC and infected cells can situmlate IL-8 production via P2 receptor signalling (4, 535 
43, 55). IL-6 is associated with activation of the acute phase response, which 536 
increases production of C-reactive protein from the liver and IL-8 acts as a 537 
chemotactic factor for neutrophils (pyuria).  The presence of pyuria in the absence of 538 
infection (determined by failure to isolate ≥105colony forming units) in a subset of 539 
OAB patients, which suggests bladder infection and IBC, is a relatively recent 540 
discovery (44).    541 
 542 
Urinary nucleotides and nucleosides as biomarkers of OAB. 543 
Previous studies have utilized the luciferin luciferase assay to investigate the 544 
potential for urinary ATP concentration to serve as a suitable biomarker for UTIs.  545 
These studies report ATP concentrations of 5-25 nM in MSU samples collected from 546 
patients testing negative for UTIs, and 112-140 nM for patients with positive culture 547 
(26, 38), suggesting that ATP could be a biomarker for urinary infection.  However, a 548 
more recent study looking at ATP concentrations in the urine of OAB patients found 549 
similar low levels of ATP in both OAB and non-OAB control groups (1.5 and 1.4 nM 550 
[normalized to creatinine concentrations], respectively) (33). Using a novel HPLC 551 
technique we found significantly higher levels of AMP in MSU samples from OAB 552 
patients (irrespective of pyuric status) than in samples from non-OAB patients.  In 553 
addition, we detected elevated adenosine in OAB patients without pyuria.  Whereas 554 
these data are currently too preliminary to propose biomarkers for OAB, it may be 555 
useful in determining additional signaling mechanisms responsible for the symptoms 556 
of OAB.  557 
 558 
Should pyuria inform the diagnosis and treatment of OAB?  559 
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Data presented here raise the question as to whether OAB with pyuria should be 560 
classified and treated differently to OAB without pyuria.  Considerable overlap 561 
already exists between OAB and chronic prostatitis or “chronic pelvic pain 562 
syndrome” and IC, also called “painful bladder syndrome”, and in all cases the 563 
diagnosis, rightly or wrongly, relies on exclusion of urinary infection by routine 564 
culture methods (54).  Our findings suggest that OAB with pyuria has a subclinical 565 
UTI component (intracellular bacteria in the urothelium), not dissimilar to recent 566 
findings for IC yet without pain and inflammation (29). That significant basal ATP 567 
release is novel to OAB with pyuria suggests treatment could be designed 568 
accordingly.  Further multi-centre investigations are required to fully answer this 569 
question; which may need to wait until routine UTI detection methodologies are 570 
updated. 571 
 572 
Summary: 573 
These data provide a better understanding of OAB aetiology and, nucleotide release 574 
and signaling in bladder epithelium (in health and disease).  The former may prompt 575 
clinical re-classification of OAB, to aid successful diagnosis and treatment in the 576 
future.  The later may help identify alternative, efficacious, and acceptable 577 
therapeutic treatments for the unpleasant symptoms of OAB.  Conceivably, efficient 578 
therapeutic strategies may be evolved to target nucleotide signaling by intravesicular 579 
delivery methods to alleviate OAB symptoms and/or treat intracellular bacteria of 580 
OAB with pyuria. 581 
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Table 1: 594 
Compound Non-OAB 
OAB 
without pyuria 
OAB
with pyuria 
ATP 1.4±0.8 nM 4.2±3.6 nM 2.0±0.8 nM 
ADP 19.0±8.5μM 11.7±2.5μM 24.2±6.5 μM 
AMP 2.7±0.5μM 14.4±8.3 μM* 8.5±2.2 μM* 
adenosine 61.0±58.5μM 228±86 μM* 113±42.3 μM 
GTP 44.9±13.9 μM 157±92.7μM 89.8±42.3 μM 
GDP 128±54.0 μM 83.2±20.0 μM 138±47.3 μM 
GMP 5.5±2.0μM 20.7±10.3 μM 15.9±6.7 μM 
guanosine 478±174 μM 225±81.5μM 527±176 μM 
UTP 9.9±2.4 μM 22.9±14.5 μM 8.6±2.6 μM 
UDP 30.6±13.9μM 20.2±6.3μM 46.5±19.3 μM 
UMP 1.4±0.6 mM 734±393 μM 667± 261 μM 
uridine 7.3±3.4μM  25.0±8.1 μM 10.0±4.8 μM 
 595 
Urinary AMP levels are elevated in OAB patients presenting with pyuria.  HPLC was 596 
used to measure the concentration of nucleotides and nucleosides in urine samples 597 
from non-OAB patients, OAB patients without pyuria or with pyuria <10 wbc μl-1 598 
(OAB without pyuria), or with pyuria≥10 wbc μl-1 (OAB with pyuria). Creatinine levels 599 
were similar in all 3 patient groups (non-OAB, 119±25 mg/dl; OAB without pyuria, 600 
132±20 mg/dl; OAB with pyuria, 121±14 mg/dl).  Data are mean±SEM (n=11 for non-601 
OAB, n=16 for OAB without pyuria, n=17 for OAB with pyuria).  * denotes statistical 602 
difference from non-OAB patients (P<0.05). 603 
604 
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Appendix: 605 
Human P2 receptor primers and mRNA accession numbers.  Primers were designed 606 
using Primer 3 Web software (Whitehead Institute for Biomedical Research, 607 
Cambridge, USA) and manufactured by Eurofins-MWG (Ebersberg, Germany). 608 
Gene Accession No. 5’to 3’ Sequence Position 
P2X1 NM_002558 S: CGCCTTCCTCTTCGAGTATGA
AS: AGATAACGCCCACCTTCTTATTAC 
471-491 
538 – 514 
P2X2 NM_170682 S: GCCTACGGGATCCGCATT
AS: TGGTGGGAATCAGGCTGAAC 
958 – 975 
1024– 1005 
P2X3 NM_002559 S: GCTGGACCATCGGGATCA
AS: GAAAACCCACCCTACAAAGTAGGA 
135 – 152 
205 – 182 
P2X4 NM_002560 S: CCTCTGCTTGCCCAGGTACTC
AS: CCAGGAGATACGTTGTGCTCAA 
1108– 1128 
1176– 1155 
P2X5 NM_002561 S: CTGCCTGTCGCTGTTCGA
AS: GCAGGCCCACCTTCTTGTT 
311 – 328 
378 – 360 
P2X6 AF065385 S: AGGCCAGTGTGTGGTGTTCA
AS: TCTCCACTGGGCACCAACTC 
488 – 507 
555 – 536 
P2X7 NM_002562 S: TCTTCGTGATGACAAACTTTCTCAA
AS: GTCCTGCGGGTGGGATACT 
401 – 425 
476 – 458 
P2Y1 NM_002563 S: CGTGCTGGTGTGGCTCATT
AS: GGACCCCGGTACCTGAGTAGA 
1352 – 1370 
1419 – 1399 
P2Y2 NM_176072 S:GAACTGACATGCAGAGGATAGAAGAT
AS: GCCGGCGTGGACTCTGT 
1495 – 1520 
1567 – 1551 
P2Y4 NM_002565 S: CCGTCCTGTGCCATGACA
AS: TGACCGCCGAGCTGAAGT 
725 – 742 
793 – 776 
P2Y6 NM_176797 S: GCCGGCGACCACATGA
AS: GACCCTGCCTCTGCCATTT 
1171 – 1186 
1227 – 1209 
P2Y11 NM_002566 S: CTGGAGCGCTTCCTCTTCAC
AS: GGTAGCGGTTGAGGCTGATG 
511 – 530 
586 – 567 
P2Y12 NM_022788 S: AGGTCCTCTTCCCACTGCTCTA
AS: CATCGCCAGGCCATTTGT 
318 – 339 
385 – 368 
P2Y13 NM_023914 S: GAGACACTCGGATAGTACAGCTGGTA
AS: GCAGGATGCCGGTCAAGA 
223 – 248 
291 – 274 
P2Y14 NM_014879 S: TTCCTTTCAAGATCCTTGGTGACT
AS: GCAGAGACCCTGCACACAAA 
433 – 456 
505 – 486 
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Figure legends: 
Figure 1.  Bladder biopsies obtained using flexible cystoscopy have full-thickness urothelium.  Human bladder 
biopsies were obtained using a flexible cystoscope under local or general anaesthetic.  Biopsies were placed in 10% 
formalin for 48 h prior to dehydration with alcohol and xylene, and parrafin wax embedding.  Sections (6 μm thick) 
were stained with H&E to investigate urothelium integrity.  (A) Representative microphotograph of a biopsy section 
from an OAB patient that presented with pyuria of <10 wbc μl-1.  Full-thickness urothelium is evident in the sample 
(between arrowheads).  (B) Representative microphotograph of a biopsy section from an OAB patient that 
presented with pyuria of ≥10 wbc μl-1.  Full-thickness urothelium is evident in the sample (as in A); umbrella cells 
lining the luminal membrane are clearly visible (arrowheads).  Scale bars equal 200 μm. 
 
Figure 2. Greater ATP release from urothelium of OAB patients with pyuria of ≥10 wbc μl-1.  ATP release from 
microdissected urothelium was measured using a luciferin luciferase asssay.  ATP release was first measured at rest 
(classified here as ‘basal’ release) and then after addition of a hypotonic solution (to cause cell stretch and mimic 
bladder filling; classified here as ‘stimulated’ release).  Data for stimulated ATP release is presented following 
subtraction of basal release values.  (A) Basal ATP release from urothelium of OAB patients with pyuria ≥10 wbc μl-1 
(OAB + pyuria; n=15) was significantly greater than basal ATP release from urothelium of OAB patients without 
pyuria, or with pyuria <10 wbc μl-1 (OAB - pyuria; n=9), or non-OAB patients (P<0.05; n=9).  (B) Stimulated ATP 
release from the urothelium was not significantly different between experimental groups (non-OAB patients, n=9; 
OAB patients without pyuria, n=9; OAB patients with pyuria, n=15).  (C) The rate at which the concentration of ATP 
decreased, following stimulation and in the continued presence of hypotonic solution, was greatest from 
urothelium of non-OAB patients (n=9) and OAB patients with pyuria (n=15).  The decreased rate of stimulated ATP 
degradation seen from urothelium of OAB patients without pyuria (n=9), was similar to that from urothelium of 
non-OAB patients in the presence of the ATPase inhibitor ARL 67156 (100 μM, n=5).  Data shown are mean±SEM. * 
denotes significant difference from non-OAB, where P<0.05.  In (A) and (B) data were compared by using one-way 
ANOVA and Dunnett’s post-hoc test against non-OAB (the identified control); in (C) data were compared by using 
two-way ANOVA (time after stimulation being the repeated measures factor, and the between factor being the 
patient conditions) and Dunnett’s post-hoc test against non-OAB (identified control). 
 
Figure 3. Mechanisms of ATP release from urothelium of OAB patients with pyuria.  ATP release from microdissected 
urothelium of OAB patients with pyuria ≥10 wbc μl-1 (OAB + pyuria) was measured using a luciferin luciferase asssay.  
ATP release was first measured at rest (‘basal’) or after addition of a hypotonic solution (‘stimulated’).  Data for 
stimulated ATP release is represented following subtraction of basal release values.  Urothelium was pre-treated 
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with the stated drug for 5 min prior to measuring ATP release (basal or stimulated).  (A) Basal ATP release from 
urothelium was significantly attenuated by both suramin (1 mM, n=3) and carbenoxolone (CBX, 50 μM, n=3), and 
significantly potentiated by UTP (1 μM, n=3) (P<0.05 in all cases).  The potentiating effects of UTP were inhibited by 
co-treatment with either CBX or suramin.  (B) Stimulated ATP release from the urothelium was significantly 
attenuated by suramin (n=5), botulinum toxin-A (BTX-A, 20 units/ml, n=3) or brefeldin-A (BFA, 20 μM, n=3) (P<0.05 
in all cases).  Co-treatment of either BFA or suramin with UTP (n=3 in both cases) had no further effect.  Data shown 
are mean±SEM. * denotes P<0.05.  In (A) and (B) data were compared by using one-way ANOVA and Dunnett’s 
post-hoc test against non-OAB (the identified control). 
 
Figure 4.  Urothelial cell stretch evokes vesicular release of ATP.  Human bladder biopsies were obtained using a 
flexible cystoscope under local anaesthetic.  Biopsies were placed in 10% formalin for 48 h prior to dehydration with 
alcohol and xylene, and paraffin wax embedding.  In some cases, biopsies were challenged with a hypotonic 
solution (to cause cell stretch and mimic bladder filling) prior to fixation.  Sections (6 μm thick) were stained with 
DAPI and quinacrine to investigate localisation of ATP-containing vesicles.  (A) Representative microphotograph of a 
biopsy section from an OAB patient with pyuria ≥10 wbc μl-1;  i) DAPI staining (blue), ii) quinacrine staining (green), 
iii) composite image of DAPI and quinacrine staining, iv) bright field image.  ATP containing vesicles are evident 
throughout the urothelium.  (B) Representative microphotograph of a biopsy section from an OAB patient with 
pyuria ≥10 wbc μl-1, challenged with a hypotonic solution prior to fixation; i) - iv) as above.  ATP containing vesicles 
are less evident throughout the urothelium.  Scale bars equal 100 μm. 
 
Figure 5.  Altered P2Y receptor expression in urothelium of OAB patients. RT-PCR was performed on microdissected 
urothelium of non-OAB patients, OAB patients without pyuria, or with pyuria <10 wbc μl-1 (OAB – pyuria), and OAB 
patients with pyuria ≥10 wbc μl-1 (OAB + pyuria).  The ratio of the P2 receptor gene of interest to a constitutively 
expressed housekeeping gene (GAPDH) was calculated. (A) Ionotropic P2X receptor mRNA levels were similar in 
urothelium from the three experimental groups (n=6).  (B) Urothelium from OAB patients without pyuria showed a 
significant increase in abundance of metabotropic P2Y11 and 13 mRNA (n=6; P<0.01).  Whereas, urothelium from OAB 
patients with pyuria showed a significant increase in abundance of metabotropic P2Y2 and 11 mRNA (n=6; P<0.01). 
Data shown are mean±SEM. * denotes significant difference from non-OAB, where P<0.01.  In (A) and (B), data 
were compared by using one-way ANOVA and Dunnett’s post-hoc test against basal or stimulated, respectively (the 
identified controls). 
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Figure 6.  Intracellular bacteria identified in shed urothelial cells from OAB patients with pyuria ≥10 wbc μl-1. Fresh 
urine was spun onto slides using a cytospin and the deposit stained with acridine orange (which fluoresces green in 
the presence of viable organism DNA).  In order to differentiate extracellular from intracellular bacteria, a crystal 
violet counter-stain was added to quench the fluorescence of extracellular microorganisms.  Images were acquired 
using an upright fluorescence microscope.  Intracellular bacteria were not observed in sedimentary cells from the 
urine of non-OAB patients (see A for a representative image) or OAB patients without pyuria, or with pyuria <10 
wbc μl-1 (OAB – pyuria; see B for a representative image).  (C) Representative microphotograph of shed urothelial 
cell colonized by intracellular bacteria (arrow) from an OAB patient with pyuria ≥10 wbc μl-1 (OAB + pyuria).  
Bacterial colonization of urothelial  cells was seen in 81% of urine samples tested (n=16), and of those, 52±9% of 
urothelial cells contained bacteria (19±3 urothelial cells per sample).  Further confirmation of the intracellular 
localisation of bacteria and cell type was obtained by treatment with anti-uroplakin III (red; a marker of urothelial 
cells) and DAPI (blue; marker of DNA).  Images were acquired with a confocal microscope and Z-series processed 
using Volocity software.  (D) Representative 2D microphotograph of three shed urothelial cells from urine of an OAB 
patient with pyuria (Di), whereby the intracellular localisation of bacteria is evident in the side projections (Dii and 
Diii; dashed line shows origin of side-projection).  Scale bars equal 10 μm. 
 
Figure 7.  Proposed mechanisms of ATP release from urothelium of OAB patients with pyuria.  In our investigations, 
basal release of ATP was ~15-fold greater from urothelium of OAB patients with pyuria, nearing levels normally 
associated with stretch and bladder fullness.  Histology demonstrates that bacteria reside in urothelial cells, and RT-
PCR suggest that levels of P2Y2 and P2Y11 are increased. (A) When the bladder is at rest there is a substantial release 
of ATP (basal release) from the urothelium, which in our experiments is abolished by CBX, suggesting release via 
hemichannels (1.).  We propose that the released ATP acts in a paracrine/autocrine fashion to activate P2 receptors 
expressed throughout the urothelium (including the upregulated P2Y2 and P2Y11 subtypes) (2.).  P2 receptor 
activation in turn evokes further ATP release (in our experiments attenuated by suramin and potentiated by UTP) 
via an undetermined mechanism (3.).  Presumably, released ATP reaches levels able to activate P2 receptors 
expressed on suburothelial sensory nerves, resulting in inappropriate signalling normally associated with bladder 
fullness (4.).  We hypothesise that the presence of intracellular bacteria (IB) is responsible for increased P2 receptor 
expression and hemichannel mediated ATP release.  (B) When the urothelium is stretched (i.e. when the bladder is 
full) there is a substantial release of ATP (stimulated release), which in our experiments is abolished by BTX-A or 
BFA, suggesting release from vesicles (1.).  We propose that the released ATP acts in a paracrine/autocrine fashion 
to activate P2 receptors expressed throughout the urothelium (2.).  P2 receptor activation in turn evokes further 
ATP release (in our experiments attenuated by suramin) again from vesicles (3.).  Presumably, released ATP reaches 
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levels able to activate P2 receptors expressed on suburothelial sensory nerves, resulting in signalling of bladder 
fullness (4.).  The presence of intracellular bacteria (IB) does not appear to alter stimulated ATP release from 
urothelium. 
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